Azacitidine ADVAGEN approved in Singapore

July 23, 2021

ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Azacitidine ADVAGEN, is now approved in Singapore.

“We are glad to be able to provide more treatment options for both our patients and doctors with the registration approval of Azacitidine. As a company, we continue to strive for timely supply of safe, effective, and affordable medication for all.” – Soo Wei, Regulatory Affairs